Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track DYAI with free AI briefings, catalyst countdowns, and dilution alerts.

DYAI · DYADIC INTERNATIONAL INC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$4.6M Cash on Hand
8.3mo Cash Runway
Follow DYAI by email Get an email when DYAI reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about DYAI, unsubscribe in one click. Privacy

📣 What DYAI Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

DYAI holds $4.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $1.7M/quarter from operations, an estimated runway of 8.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 67 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when DYAI files for a raise →

👥 Who Owns DYAI

Insiders 25.5% Institutions (43 holders) 19.1% Public and other holders 55.4%
HolderTypeShares% of sharesAs of
Mark A Emalfarb
CEO, Director, 10% owner · +498,000 options
Insider 4,832,667 12.05% 2026-01-02
Francisco Trust under agreement dated Fe
10% owner · +2.23M options
Insider 4,232,653 10.56% 2026-08-14
Empery Asset Management, LP Institution (13G, 5%+) 3,346,275 8.35% 2026-09-30
Michael P. Tarnok
Director · +79,375 options
Insider 281,033 0.70% 2025-06-20
Seth Herbst
Director · +139,894 options
Insider 202,311 0.50% 2026-01-02
Joseph P Hazelton
President & COO · +262,250 options
Insider 191,758 0.48% 2026-01-02
Ping Wang Rawson
Chief Financial Officer · +186,750 options
Insider 170,151 0.42% 2026-01-02
Jack Kaye
Director · +174,894 options
Insider 81,201 0.20% 2026-01-02
Patrick K. Lucy
Director · +188,019 options
Insider 72,311 0.18% 2026-01-02
Arindam Bose
Director · +135,000 options
Insider 61,535 0.15% 2025-06-20
Ronen Tchelet
VP of Research and Bus. Dvlpmt · +92,250 options
Insider 50,897 0.13% 2026-01-02
Barry Buckland
Director · +38,967 options
Insider 38,967 0.10% 2024-06-11

Share count 40,091,203 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full DYAI picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for DYAI and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.